The heart is the most vital organ of the body that pumps blood to every other organ. Any aberration in the normal functioning of the heart can lead to serious pathological conditions which might permanently impact the functioning of other organs. At present, heart attack or myocardial infarction has become a critical global health issue Continue reading →

Abstract BACKGROUND: There is a paucity of population-based geospatial data about the association between active transport andmyocardial infarction. We investigated the association between active transport to work and incidence ofmyocardial infarction. Continue reading →

1. The ISCHEMIA Trial The ISCHEMIA trial transcends the cath lab and influences much of cardiology practice. Its findings also reach into human psychology. Continue reading →

BACKGROUND: Although many observational studies have shown an association between plasma homocysteine levels and cardiovascular diseases, controversy remains. Continue reading →

The Food and Drug Administration (FDA) has approved the use of Vascepa (icosapent ethyl; Amarin Pharma) as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (150mg/dL) and established CV disease or diabetes mellitus and 2 or more additional risk factors for CV disease. The approval was based on data from the phase 3 REDUCE-IT trial that assessed the CV outcomes of 8179 patients who were administered Vascepa as an add-on to statins, and who had elevated TG levels (135mg/dL) with either CV disease or diabetes and other CV risk factors. The primary composite end point included time to first occurrence of CV death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina (5-point major adverse cardiovascular event [MACE]) Continue reading →

A leading research firm, Zion Market Research added a latest industry report on "Global Myocardial Infarction Treatment Market" consisting of 110+ pages during the forecast period and Myocardial Infarction Treatment Market report offers a comprehensive research updates and information related to market growth, demand, opportunities in the global Myocardial Infarction Treatment Market. According to the report the Myocardial Infarction Treatment Market to Witness Comprehensive Growth By 2024 The Myocardial Infarction Treatment Market report provides in-depth analysis and insights into developments impacting businesses and enterprises on global and regional level. The report covers the global Myocardial Infarction Treatment Market performance in terms of revenue contribution from various segments and includes a detailed analysis of key trends, drivers, restraints, and opportunities influencing revenue growth of the global consumer electronics market.This report studies the global Myocardial Infarction Treatment Market size, industry status and forecast, competition landscape and growth opportunity Continue reading →

BACKGROUND: Survival benefit of revascularization over medical therapy (MT) in patients with stable ischemic heart disease (SIHD) is uncertain. We evaluated the prognostic effects of revascularization in patients with SIHD undergoing single-photon emission computed tomographymyocardialperfusion imaging (SPECT-MPI) Continue reading →

The Food and Drug Administration (FDA) has approved the use of Vascepa (icosapent ethyl; Amarin Pharma) as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (150mg/dL) and established CV disease or diabetes mellitus and 2 or more additional risk factors for CV disease. The approval was based on data from the phase 3 REDUCE-IT trial that assessed the CV outcomes of 8179 patients who were administered Vascepa as an add-on to statins, and who had elevated TG levels (135mg/dL) with either CV disease or diabetes and other CV risk factors. The primary composite end point included time to first occurrence of CV death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina (5-point major adverse cardiovascular event [MACE]) Continue reading →